Response of eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia: A single-center experience

Authors

Abdul Muqtadir Abbasi, Aga Khan University
Mohammad Usman Shaikh, Aga Khan UniversityFollow
Natasha Bahadur Ali, Aga Khan UniversityFollow
Maria Khan, Aga Khan UniversityFollow
Salman Muhammad Soomar, Aga Khan UniversityFollow

Document Type

Article

Department

Haematology/Oncology; Pathology and Laboratory Medicine; Medical College Pakistan

Abstract

Eltrombopag has been used in ITP and found its use in AA armamentarium recently. We retrospectively analyzed 61 patients at a tertiary care center in Pakistan from January 2015 to January 2021. They included patients with severe AA who were refractory to at least one course of immunosuppressive therapy and persistent/chronic ITP who have received at least one previous treatment for ITP. Responses to Eltrombopag in our population were comparable to real-world experiences while tolerable hepatotoxicity and GI issues were notable. We found Eltrombopag to be a safe and efficacious agent for treating patients with ITP and AA.

Comments

Issue, and pagination are not provided by the author/publisher

Publication (Name of Journal)

Leukemia Research Reports

Recommended Citation

Abbasi, A. M., Shaikh, M., Ali, N., Khan, M., Soomar, S. M. (2022). Response of eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia: A single-center experience. Leukemia Research Reports, 17, 100295.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_med_haematol_oncol/78

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.